Text Size

Anesthesia and Lymphocytes Apoptosis (OPCAB)

This study is currently recruiting participants.
Verified October 2011 by Ruijin Hospital
Sponsor:
Information provided by (Responsible Party):
Li-Jie Jia, Ruijin Hospital
ClinicalTrials.gov Identifier:
NCT01461551
First received: October 19, 2011
Last updated: October 29, 2011
Last verified: October 2011
History of Changes

October 19, 2011
October 29, 2011
October 2011
January 2012   (final data collection date for primary outcome measure)
lymphocyte count [ Time Frame: 1 day after surgery ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01461551 on ClinicalTrials.gov Archive Site
hospital days [ Time Frame: participants will be followed for the duration of hospital stay, an expected average of 2 weeks ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Anesthesia and Lymphocytes Apoptosis
Different Effects of Sevoflurane, Propofol and Combine of Sevoflurane and Propofol Maintained Anesthesia on Peripheral Blood Lymphocytes During Off-pump Coronary Artery Bypass Graft Surgery

Most researches revealed that volatile anesthetic sevoflurane has a more marked cardioprotective effect against ischemia compared with intravenous agent propofol.However, propofol has been suggested to be more benefit for attenuation of surgery-induced immunosuppression.Thus, the aim of this study was to investigate under the specific OPCAB surgical stress, the influence of 3 established anesthetic techniques: sevoflurane, propofol and combine of sevoflurane and propofol maintained anesthesia on the apoptosis of circulating lymphocytes.
Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Prevention
Anesthesia
  • Drug: Sevoflurane
    anesthesia was maintained with sevoflurane (end-tidal concentration 1.0-1.5 minimum alveolar concentration)
  • Drug: Propofol
    anesthesia was maintained with propofol (2-4 μg/ml via target-controlled infusion)
  • Drug: combine of sevoflurane and propofol
    anesthesia was maintained with a combine of propofol (1 μg/ml via target-controlled infusion) and sevoflurane (end-tidal concentration 0.7-1.0 minimum alveolar concentration)
  • Experimental: Sevoflurane
    Intervention: Drug: Sevoflurane
  • Experimental: Propofol
    Intervention: Drug: Propofol
  • Experimental: Combine of sevoflurane and propofol
    Intervention: Drug: combine of sevoflurane and propofol
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
105
February 2012
January 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • male adults
  • aged 18-80 yr
  • undergoing elective OPCAB surgery containing left anterior descending artery bypass

Exclusion Criteria:

  • a previous unusual response to any of the experimental anesthetics
  • severe cardiac dysrhythmias or ejection fraction below 30%
  • hemodynamic instability
  • previous surgical coronary artery repair
  • anemia, abnormal leukocytes or coagulopathy
  • severe hypertension
  • severe hepatic (albumin<30g,ascites), renal (serum creatinine greater than 2.0 mg/dl) or pulmonary (preoperative pulmonary function tests moderate-severe) dysfunctions
  • concomitant surgical procedures and psychiatric disorders
  • Insulin-dependent diabetics
Male
18 Years to 80 Years
No
Contact: Han Lu, Ph.D. 64370045 ext 666225 luhan0301@163.com
China
 
NCT01461551
OPCAB
Yes
Li-Jie Jia, Ruijin Hospital
Ruijin Hospital
Not Provided
Study Director: Bu-Wei Yu, Ph.D., M.D. Department of Anesthesiology, Ruijin Hospital, Shanghai Jiao tong University School of Medicine
Ruijin Hospital
October 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP